VANGL2

Across TCGA pan-cancer cohorts, VANGL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated VANGL2 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VANGL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated VANGL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

PDAC, LSCC, and GBM are the cancer types where VANGL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.336	0.921	.017	18	view →
LSCC	DFS	Tertile	III,IV	1.000	0.454	.009	17	view →
GBM	DFS	Tertile	All	0.856	0.711	.011	6	view →
LUAD	DFS	Quartile	II,III,IV	0.552	1.000	.031	4	view →
CCRCC	OS	Median	All	1.000	0.567	.023	3	view →
HNSC	DFS	Median	IV	0.607	0.783	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

VANGL2–PDAC (OS)

Open the PDAC breakdown →